Voluntary nationwide recall: Prograf and Astagraf (Astellas – December)

Jan. 2025Pharmacy Updates

Astellas Pharma US, Inc. is recalling one lot of Prograf, lot 0E3353D, and one lot of Astagraf XL, lot 0R3092A. Prograf and Astagraf XL are used in conjunction with other medicines to help prevent organ transplant rejection.

These drugs are being recalled because bottles may contain empty capsules. Using empty capsules may result in organ transplant rejection that may be fatal.

To see if your medication was recalled, contact your doctor or pharmacy where you received it or visit the FDA website below. If you have an affected lot of Prograf or Astagraf XL, you should stop using the product and contact your pharmacy where you received it for a replacement.

As of Dec. 26, there had been no reports of adverse events related to this recall.

To learn more about this recall, you can take one or more of the steps below.

  • Talk to your doctor or pharmacist.
  • Call Astellas Medical Information at 1-800-727-7003. TTY users should call 711. Help is available Monday through Friday from 9 a.m. to 5:30 p.m. EST.
  • Visit the FDA website.

Recent Announcements

CME Webinar: The State of Telehealth in 2026

Please join us for a live, CME-accredited webinar on Tuesday, Jan. 27, from noon to 1 p.m. that will share updates on the state of telehealth for 2026.
Dec. 2025Education/Webinars

Formulary updates effective Jan. 1, 2026

Review upcoming policy and operational updates
Dec. 2025Pharmacy Updates

Voluntary nationwide recall: Famotidine (Fresenius – November)

Fresenius Kabi USA, LLC is recalling three lots (6133156, 6133194, and 6133388) of Famotidine Injection, USP, 20 mg per 2 mL. Famotidine is used to treat excessive secretion of stomach acid or stomach ulcers.
Nov. 2025Pharmacy Updates